Barriers, Enablers and Strategies for the Treatment and Control of Hypertension in Nepal: A Systematic Review.

Raja Ram Dhungana, Zeljko Pedisic, Achyut Raj Pandey, Nipun Shrestha, Maximilian de Courten
Author Information
  1. Raja Ram Dhungana: Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  2. Zeljko Pedisic: Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  3. Achyut Raj Pandey: Nepal Health Research Council, Kathmandu, Nepal.
  4. Nipun Shrestha: Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  5. Maximilian de Courten: Mitchell Institute for Education and Health Policy, Victoria University, Melbourne, VIC, Australia.

Abstract

Understanding country-specific factors influencing hypertension care is critical to address the gaps in the management of hypertension. However, no systematic investigation of factors influencing hypertension treatment and control in Nepal is available. This study aimed to systematically review the published literature and synthesise the findings on barriers, enablers, and strategies for hypertension treatment and control in Nepal. Embase, PubMed, Web of Science, CINAHL, ProQuest and WorldCat, and Nepali journals and government websites were searched for qualitative, quantitative, and mixed-methods studies on factors or strategies related to hypertension treatment and control in Nepal. Information from qualitative studies was analysed using template analysis, while results from quantitative studies were narratively synthesised. Summary findings were framed under "health system", "provider", and "patient" domains. The protocol was registered in PROSPERO (registration number: CRD42020145823). We identified 15 studies; ten related to barriers and enablers and five to strategies. The identified barriers associated with the health system were: lack of affordable services and lack of resources. The barriers at the provider's level were: communication gaps, inadequate counselling, long waiting hours for appointments, lack of national guidelines for hypertension treatment, and provider's unsupportive behaviours. Non-adherence to medication, irregular follow-up visits, lack of awareness on blood pressure target, poor help-seeking behaviours, reluctance to change behaviours, perceived side-effects of anti-hypertensive medication, self-medication, lack of family support, financial hardship, lack of awareness on blood pressure complications, and comorbidity were barriers identified at patient level. The following enablers were identified: free essential health care services, family support, positive illness perception, and drug reminders. Strategies implemented at the health system, provider and patient levels were: establishing digital health records at health centres, health worker's capacity development, and health education. There is a range of barriers for hypertension treatment and control in Nepal pertaining to the health system, health providers, and patients. Comprehensive interventions are needed at all three levels to further improve management and control of hypertension in Nepal.

Keywords

References

  1. Glob Health Action. 2014 Apr 30;7:24023 [PMID: 24802386]
  2. Front Cardiovasc Med. 2016 Aug 02;3:26 [PMID: 27532038]
  3. Am J Public Health. 2012 Dec;102(12):2242-5 [PMID: 22698017]
  4. Australas Med J. 2014 Jul 31;7(7):304-13 [PMID: 25157270]
  5. Syst Rev. 2016 Dec 5;5(1):210 [PMID: 27919275]
  6. BMC Health Serv Res. 2015 Jul 03;15:254 [PMID: 26135302]
  7. PLoS One. 2007 Mar 14;2(3):e280 [PMID: 17356691]
  8. Am J Hypertens. 2017 Apr 1;30(4):373-381 [PMID: 28096145]
  9. Circulation. 2016 Aug 9;134(6):441-50 [PMID: 27502908]
  10. Patient Educ Couns. 2019 Jun;102(6):1045-1056 [PMID: 30846205]
  11. Transl Behav Med. 2020 Aug 7;10(3):741-750 [PMID: 30947329]
  12. Ann Intern Med. 2014 Oct 21;161(8):568-78 [PMID: 25155549]
  13. Heart Asia. 2018 Aug 31;10(2):e011047 [PMID: 30233660]
  14. Ethn Dis. 2016 Jul 21;26(3):315-22 [PMID: 27440970]
  15. Heart Asia. 2017 Jan 4;9(1):1-8 [PMID: 28123454]
  16. J Hypertens. 2017 Aug;35(8):1546-1553 [PMID: 28448291]
  17. J Hum Hypertens. 2018 Apr;32(4):249-258 [PMID: 29386668]
  18. PLoS One. 2014 Jan 15;9(1):e84238 [PMID: 24454721]
  19. Expert Opin Pharmacother. 2017 Mar;18(4):377-386 [PMID: 28129695]
  20. Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9): [PMID: 28830861]
  21. JNMA J Nepal Med Assoc. 2018 Mar-Apr;56(210):633-639 [PMID: 30376011]
  22. Soc Sci Med. 2005 Jul;61(1):133-55 [PMID: 15847968]
  23. Arch Intern Med. 2002 Feb 25;162(4):413-20 [PMID: 11863473]
  24. Glob Heart. 2017 Sep;12(3):233-243.e6 [PMID: 27993594]
  25. J Nepal Health Res Counc. 2015 Jan-Apr;13(29):38-42 [PMID: 26411711]
  26. Lancet Glob Health. 2019 Jun;7(6):e761-e771 [PMID: 31097278]
  27. Nepal Med Coll J. 2012 Mar;14(1):56-9 [PMID: 23441497]
  28. J Clin Hypertens (Greenwich). 2016 Mar;18(3):232-9 [PMID: 26337797]
  29. J Manag Care Pharm. 2006 Apr;12(3):239-45 [PMID: 16623608]
  30. BMJ Open. 2021 Jul 27;11(7):e047665 [PMID: 34315794]
  31. J Natl Med Assoc. 2009 Jun;101(6):597-603 [PMID: 19585931]
  32. Lancet Glob Health. 2018 Jan;6(1):e66-e73 [PMID: 29241617]
  33. PLoS Med. 2013;10(7):e1001490 [PMID: 23935461]
  34. J Hypertens. 2018 Feb;36(2):208-220 [PMID: 29120958]
  35. J Clin Diagn Res. 2017 Jun;11(6):LC01-LC05 [PMID: 28764203]
  36. J Hum Hypertens. 2018 Jul;32(7):467-476 [PMID: 29713051]
  37. Kathmandu Univ Med J (KUMJ). 2015 Jul-Sep;13(51):212-5 [PMID: 27180365]
  38. PLoS One. 2017 Oct 5;12(10):e0185806 [PMID: 28982159]
  39. Syst Rev. 2015 Jan 01;4:1 [PMID: 25554246]
  40. J Hypertens. 2018 Aug;36(8):1680-1688 [PMID: 29621067]
  41. Hypertens Res. 2020 Jul;43(7):621-628 [PMID: 32203451]
  42. Am J Prev Med. 2014 Jul;47(1):86-99 [PMID: 24933494]
  43. J Nepal Health Res Counc. 2020 Jan 21;17(4):521-527 [PMID: 32001860]
  44. Am Heart J. 2005 May;149(5):785-94 [PMID: 15894958]
  45. PLoS One. 2019 Jan 25;14(1):e0211100 [PMID: 30682093]
  46. Am J Hypertens. 2017 Sep 1;30(9):907-913 [PMID: 28531244]
  47. BMJ Glob Health. 2019 Apr 29;4(2):e001343 [PMID: 31139453]
  48. Int J Hypertens. 2016;2016:1656938 [PMID: 27293880]
  49. Br J Gen Pract. 2005 Nov;55(520):875-82 [PMID: 16282005]
  50. J Hypertens. 2012 Aug;30(8):1500-10 [PMID: 22635137]
  51. BMJ. 2012 Jul 09;345:e3953 [PMID: 22777025]
  52. J Hum Hypertens. 2019 Aug;33(8):613-625 [PMID: 30659279]
  53. Ther Clin Risk Manag. 2008 Feb;4(1):269-86 [PMID: 18728716]
  54. Annu Rev Public Health. 2014;35:399-421 [PMID: 24387091]
  55. Am J Hypertens. 2017 Dec 8;31(1):115-123 [PMID: 28985269]
  56. BMJ. 2020 Jan 16;368:l6890 [PMID: 31948937]
  57. BMJ Open. 2020 Sep 1;10(9):e040799 [PMID: 32873686]

Word Cloud

Created with Highcharts 10.0.0hypertensionhealthbarrierstreatmentcontrolNepallackstudiesfactorsenablersstrategiesidentifiedsystemwere:behavioursinfluencingcaregapsmanagementfindingsqualitativequantitativerelatedservicesprovider'slevelmedicationawarenessbloodpressurefamilysupportpatientStrategieslevelsUnderstandingcountry-specificcriticaladdressHoweversystematicinvestigationavailablestudyaimedsystematicallyreviewpublishedliteraturesynthesiseEmbasePubMedWebScienceCINAHLProQuestWorldCatNepalijournalsgovernmentwebsitessearchedmixed-methodsInformationanalysedusingtemplateanalysisresultsnarrativelysynthesisedSummaryframed"healthsystem""provider""patient"domainsprotocolregisteredPROSPEROregistrationnumber:CRD4202014582315tenfiveassociatedaffordableresourcescommunicationinadequatecounsellinglongwaitinghoursappointmentsnationalguidelinesunsupportiveNon-adherenceirregularfollow-upvisitstargetpoorhelp-seekingreluctancechangeperceivedside-effectsanti-hypertensiveself-medicationfinancialhardshipcomplicationscomorbidityfollowingidentified:freeessentialpositiveillnessperceptiondrugremindersimplementedproviderestablishingdigitalrecordscentresworker'scapacitydevelopmenteducationrangepertainingproviderspatientsComprehensiveinterventionsneededthreeimproveBarriersEnablersTreatmentControlHypertensionNepal:SystematicReviewfacilitators

Similar Articles

Cited By